• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Alaunos Therapeutics Inc. (Amendment)

    2/14/24 12:43:20 PM ET
    $TCRT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TCRT alert in real time by email
    SC 13G/A 1 d10943920_13g-a.htm

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 3)*

     

     

     

    Alaunos Therapeutics, Inc.
    (Name of Issuer)

     

     

     

    Common Stock, par value $0.001 per share
    (Title of Class of Securities)

     

     

     

    98973P101
    (CUSIP Number)

     

     

     

    December 31, 2023
    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    [ ] Rule 13d-1(b)

     

    [X] Rule 13d-1(c)

     

    [_] Rule 13d-1(d)

     

    __________

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

    CUSIP No. 98973P101    

     

    1. NAME OF REPORTING PERSONS  
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
         
      Discovery Capital Management, LLC  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)  [_]
        (b)  [x]
         
    3. SEC USE ONLY  
         
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      Connecticut  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      0  
         
    6. SHARED VOTING POWER  
         
      4,001,856  
         
    7. SOLE DISPOSITIVE POWER  
         
      0  
         
    8. SHARED DISPOSITIVE POWER  
         
      4,001,856  
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
      4,001,856  
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)      [_]
         
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      1.66%  
         
    12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)  
         
      IA  

     

     

    CUSIP No. 98973P101    

     

    1. NAME OF REPORTING PERSONS  
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
         
      Robert K. Citrone  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)  [_]
        (b)  [x]
         
    3. SEC USE ONLY  
         
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      U.S.A.  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      0  
         
    6. SHARED VOTING POWER  
         
      4,001,856  
         
    7. SOLE DISPOSITIVE POWER  
         
      0  
         
    8. SHARED DISPOSITIVE POWER  
         
      4,001,856  
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
      4,001,856  
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)      [_]
         
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      1.66%  
         
    12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)  
         
      IN, HC  

     

     

    CUSIP No. 98973P101    

     

    1. NAME OF REPORTING PERSONS  
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
         
      Discovery Global Opportunity Master Fund, Ltd.  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)  [_]
        (b)  [x]
         
    3. SEC USE ONLY  
         
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      Cayman Islands  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      0  
         
    6. SHARED VOTING POWER  
         
      4,001,856  
         
    7. SOLE DISPOSITIVE POWER  
         
      0  
         
    8. SHARED DISPOSITIVE POWER  
         
      4,001,856  
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
      4,001,856  
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)      [_]
         
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      1.66%  
         
    12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)  
         
      CO  

     

     

    CUSIP No. 98973P101  

     

    Item 1. (a). Name of Issuer:
         
        Alaunos Therapeutics, Inc.
         
      (b). Address of Issuer's Principal Executive Offices:
         
       

    8030 El Rio Street

    Houston, Texas 77054

         
    Item 2. (a) – (c) Name, Principal Business Address, and Citizenship of Persons Filing:
         
        Discovery Capital Management, LLC – Connecticut
       

    Robert K. Citrone – U.S.A.

    Discovery Global Opportunity Master Fund, Ltd. – Cayman Islands

         
       

    Discovery Capital Management, LLC

    20 Marshall Street, Suite 310

    South Norwalk, CT 06854

    United States of America

     

       

    Robert K. Citrone

    c/o Discovery Capital Management, LLC

    20 Marshall Street, Suite 310

    South Norwalk, CT 06854

    United States of America

     

       

    Discovery Global Opportunity Master Fund, Ltd.

    c/o Discovery Capital Management, LLC

    20 Marshall Street, Suite 310

    South Norwalk, CT 06854

    United States of America

         
      (d).   Title of Class of Securities:
         
        Common Stock, par value $0.001 per share
         
      (e). CUSIP Number:
         
        98973P101
         
    Item 3.   If This Statement is filed pursuant to ss.240.13d-1(b) or 240.13d-2(b), or (c), check whether the person filing is a
         

     

      (a) [_] Broker or dealer registered under Section 15 of the Exchange Act (15 U.S.C. 78c).
           
      (b) [_] Bank as defined in Section 3(a)(6) of the Exchange Act (15 U.S.C. 78c).
           
      (c) [_] Insurance company as defined in Section 3(a)(19) of the Exchange Act (15 U.S.C. 78c).
           
      (d) [_] Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
           
      (e) [X] An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
           
      (f) [_] An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
           
      (g) [X] A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
           
      (h) [_] A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C.1813);
           
      (i) [_] A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
           
      (j)   [_] Group, in accordance with s.240.13d-1(b)(1)(ii)(J).

     

     

     

     

    Item 4. Ownership.
     
    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

      (a)   Amount beneficially owned:
         
        Discovery Capital Management, LLC – 4,001,856
       

    Robert K. Citrone – 4,001,856

    Discovery Global Opportunity Master Fund, Ltd. – 4,001,856

         
      (b)   Percent of class:
         
        Discovery Capital Management, LLC – 1.66%
       

    Robert K. Citrone – 1.66%

    Discovery Global Opportunity Master Fund, Ltd. – 1.66%

         
      (c)   Number of shares as to which the person has:
         
        (i) Sole power to vote or to direct the vote  
             
          Discovery Capital Management, LLC – 0
         

    Robert K. Citrone – 0

    Discovery Global Opportunity Master Fund, Ltd. - 0

             
        (ii)   Shared power to vote or to direct the vote  
             
          Discovery Capital Management, LLC – 4,001,856
         

    Robert K. Citrone – 4,001,856

    Discovery Global Opportunity Master Fund, Ltd. - 4,001,856

             
        (iii) Sole power to dispose or to direct the disposition of  
             
          Discovery Capital Management, LLC – 0
         

    Robert K. Citrone – 0

    Discovery Global Opportunity Master Fund, Ltd. - 0

             
        (iv)   Shared power to dispose or to direct the disposition of  
             
          Discovery Capital Management, LLC – 4,001,856
         

    Robert K. Citrone – 4,001,856

    Discovery Global Opportunity Master Fund, Ltd. - 4,001,856

     

     
    Item 5. Ownership of Five Percent or Less of a Class.
     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [X].
     
       
       
       

     

     

     

     

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than five percent of the class, such person should be identified.  A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
     
      N/A.
       
       

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.
     
    If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(1)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary.  If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.
     
      See Exhibit B attached hereto.
       
       

     

    Item 8. Identification and Classification of Members of the Group.
     
    If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group.  If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.
     
      N/A
       
       

     

    Item 9. Notice of Dissolution of Group.
     
    Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity.  See Item 5.
     
      N/A
       
       

     

    Item 10. Certification.
     
      (a)   Certification by Discovery Capital Management, LLC and Robert K. Citrone:
         
        By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
         

     

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

      February 14, 2024
      (Date)
       
       
      Discovery Capital Management, LLC
       
      By:  /s/ Robert K. Citrone
      (Signature)
       
      Principal
      (Name/Title)
       
      Discovery Global Opportunity Master Fund, Ltd.
       
      By:  /s/ Robert K. Citrone
      (Signature)
       
      Director
      (Name/Title)
       
      /s/ Robert K. Citrone
      (Signature)

     

    The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

    Note. Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See s.240.13d-7 for other parties for whom copies are to be sent.

    Attention. Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 1001).

     

     

     

     

     

    EXHIBIT A

     

    AGREEMENT

     

    The undersigned agree that this Schedule 13G Amendment No. 3 dated February 14, 2024 relating to the Common Stock, par value $0.001 per share of Alaunos Therapeutics, Inc. shall be filed on behalf of the undersigned.

     

      February 14, 2024
      (Date)
       
       
      Discovery Capital Management, LLC
       
      By:  /s/ Robert K. Citrone
      (Signature)
       
      Principal
      (Name/Title)
       
      Discovery Global Opportunity Master Fund, Ltd.
       
      By:  /s/ Robert K. Citrone
      (Signature)
       
      Director
      (Name/Title)
       
      /s/ Robert K. Citrone
      (Signature)

     

     

     

     

     

     

    EXHIBIT B

     

    Discovery Capital Management, LLC is the relevant entity for which Robert K. Citrone may be considered a control person.

     

     

     

     

     

     

    Get the next $TCRT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TCRT

    DatePrice TargetRatingAnalyst
    10/4/2022$3.00Overweight
    Wells Fargo
    More analyst ratings

    $TCRT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Wells Fargo resumed coverage on Alaunos Therapeutics with a new price target

      Wells Fargo resumed coverage of Alaunos Therapeutics with a rating of Overweight and set a new price target of $3.00

      10/4/22 7:18:05 AM ET
      $TCRT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TCRT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Alaunos Therapeutics Announces Third Quarter 2023 Financial Results, Phase 1 Clinical Data and Continued Exploration of Strategic Alternatives

      TCR-T Library Phase 1/2 trial achieved an 87% disease control rate of eight evaluable patients with metastatic, refractory solid tumors; TCR-T cell therapy was well tolerated in all treated patientshunTR® discovered new HLA class I and class II restricted TCRs that recognize driver mutations, including KRAS and TP53Company continues to explore potential strategic alternatives; cost-savings measures expected to extend cash runaway into the second quarter of 2024 HOUSTON, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. ("Alaunos" or the "Company") (NASDAQ:TCRT), today announced financial results for the third quarter ended September 30, 2023. As previously announced, the Compan

      11/14/23 7:30:00 AM ET
      $TCRT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alaunos Therapeutics Announces Second Quarter 2023 Financial Results, Interim Clinical Data and Exploration of Strategic Alternatives

      TCR-T Library Phase 1/2 trial achieved an 83% disease control rate of six evaluable patients with metastatic, refractory solid tumors; TCR-T cell therapy was well tolerated in all evaluable patientsCompany to wind down TCR-T Library Phase 1/2 trial and concurrently explore potential partnering opportunities for the hunTR® platform as well as broad strategic alternativesReducing headcount by approximately 60% while retaining key hunTR® R&D capabilities HOUSTON, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. ("Alaunos" or the "Company") (NASDAQ:TCRT), today announced financial results for the second quarter ended June 30, 2023. The Company also announced a strategic repriori

      8/14/23 4:05:34 PM ET
      $TCRT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alaunos Therapeutics Announces Presentation at the 2nd Hawaii Global Summit on Thoracic Malignancies

      HOUSTON, June 29, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. ("Alaunos" or the "Company") (NASDAQ:TCRT), a leading T-cell receptor (TCR) cell therapy company advancing a clinical-stage pipeline of therapeutics for solid tumors, today announced that the Company will present at the 2nd Hawaii Global Summit on Thoracic Malignancies taking place June 27 – July 1, 2023. Alaunos Director of Translational Sciences Matthew Collinson-Pautz, Ph.D., will discuss the Company's TCR-T therapy in solid tumors targeting specific, cancer-driving mutations currently being evaluated in a Phase 1/2 open-label, dose-escalation trial at The University of Texas MD Anderson Cancer Center. Details of th

      6/29/23 7:00:53 AM ET
      $TCRT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TCRT
    Financials

    Live finance-specific insights

    See more
    • Alaunos Therapeutics Reports First Quarter 2023 Financial Results

      Actively enrolling patients and manufacturing cryopreserved products for TCR-T Library Phase 1/2 trial; expect to report interim data in the third quarter of 2023Fully prepaid loan with Silicon Valley Bank; now a debt-free companyAmended exclusive licensing agreement with Precigen, Inc., reflecting the Company's focus on its TCR-T programs and eliminating long-term financial obligationsCompany to host conference call today at 9:00 a.m. ET HOUSTON, May 10, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. ("Alaunos" or the "Company") (NASDAQ:TCRT), a leading T-cell receptor (TCR) cell therapy company advancing a clinical-stage pipeline of therapeutics for solid tumors, today announce

      5/10/23 7:00:17 AM ET
      $TCRT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alaunos Therapeutics to Report First Quarter 2023 Financial Results on May 10, 2023

      HOUSTON, May 03, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. ("Alaunos" or the "Company") (NASDAQ:TCRT), a leading T-cell receptor (TCR) cell therapy company advancing a clinical-stage pipeline of therapeutics for solid tumors, today announced that it will report financial results for the first quarter ended March 31, 2023, on Wednesday, May 10, 2023, before the open of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 9:00 a.m. ET to review the financial results and provide a corporate update. Register for the live webcast using the link here or by visiting the "Investors" section of the Alaunos website at www.alaunos.com. To partici

      5/3/23 8:30:00 AM ET
      $TCRT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alaunos Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on March 7, 2023

      HOUSTON, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. ("Alaunos" or the "Company") (NASDAQ:TCRT), a clinical-stage oncology-focused cell therapy company, today announced that it will report financial results for the fourth quarter and full year ended December 31, 2022, on Tuesday, March 7, 2023, before the open of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 8:30 a.m. ET to review the financial results and provide a corporate update. Register for the live webcast using the link here or by visiting the "Investors" section of the Alaunos website at www.alaunos.com. To participate via telephone, please register in advance at

      2/28/23 4:01:07 PM ET
      $TCRT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TCRT
    Leadership Updates

    Live Leadership Updates

    See more
    • Alaunos Therapeutics Appoints Dr. Robert J. Hofmeister to Board of Directors

      HOUSTON, March 30, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. ("Alaunos" or the "Company") (NASDAQ:TCRT), a leading T-cell receptor (TCR) cell therapy company advancing a clinical-stage pipeline of therapeutics for solid tumors, today announced the appointment of Robert J. Hofmeister, PhD, MS, Chief Scientific Officer of a stealth early stage biotechnology company, to the Company's Board of Directors, effective immediately. Dr. Hofmeister will replace Chris Bowden, MD. "We extend our gratitude to Chris for his invaluable contributions to Alaunos during his tenure, and welcome Robert to the Alaunos Board," said Kevin S. Boyle, Sr., Chief Executive Officer of Alaunos. "Robert bring

      3/30/23 7:00:40 AM ET
      $TCRT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alaunos Therapeutics Appoints Abhishek Srivastava, Ph.D. as Vice President, Technical Operations

      HOUSTON, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. ("Alaunos" or the "Company") (NASDAQ:TCRT), a clinical-stage oncology-focused cell therapy company, today announced the appointment of Abhishek Srivastava, Ph.D. as Vice President of Technical Operations. Dr. Srivastava will lead the Company's manufacturing operations, including overseeing process optimization and capacity expansion. "Abhi brings extensive experience in cell therapy technical operations, and I am pleased to welcome him to our team," commented Kevin S. Boyle, Sr., Chief Executive Officer of Alaunos. "He joins Alaunos at an exciting time as we continue to advance development of our promising TCR T Library

      8/4/22 5:00:00 PM ET
      $TCRT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CARsgen Appoints Dr. Raffaele Baffa as Chief Medical Officer

      SHANGHAI and BOSTON, April 7, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T cell therapies for the treatment of hematologic malignancies and solid tumors, announces that Dr. Raffaele Baffa ("Dr. Baffa") has been appointed as the Chief Medical Officer ("CMO") of the Company, responsible for overseeing the global clinical development strategies and operations for the Company's innovative pipeline product candidates. Dr. Baffa will report to Dr. Zonghai Li, Founder, Chairman of the Board, CEO, CSO of CARsgen Therapeutics Holdings Limited. Dr. Baffa has rich experiences in pharmaceutical industry and research institutes,

      4/7/22 11:42:00 AM ET
      $TCRT
      $ZIOP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TCRT
    SEC Filings

    See more
    • SEC Form PRE 14A filed by Alaunos Therapeutics Inc.

      PRE 14A - Alaunos Therapeutics, Inc. (0001107421) (Filer)

      5/9/25 9:09:41 AM ET
      $TCRT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form 10-K/A filed by Alaunos Therapeutics Inc.

      10-K/A - Alaunos Therapeutics, Inc. (0001107421) (Filer)

      4/30/25 4:59:30 PM ET
      $TCRT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alaunos Therapeutics Inc. filed SEC Form 8-K: Leadership Update

      8-K - Alaunos Therapeutics, Inc. (0001107421) (Filer)

      4/18/25 4:45:08 PM ET
      $TCRT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TCRT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Postma Robert W was granted 20,804 shares, increasing direct ownership by 251% to 29,083 units (SEC Form 4)

      4 - Alaunos Therapeutics, Inc. (0001107421) (Issuer)

      4/15/25 8:42:09 PM ET
      $TCRT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Weis Holger

      4 - Alaunos Therapeutics, Inc. (0001107421) (Issuer)

      4/15/25 8:33:33 PM ET
      $TCRT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Vieser Jaime was granted 17,465 shares, increasing direct ownership by 67% to 43,359 units (SEC Form 4)

      4 - Alaunos Therapeutics, Inc. (0001107421) (Issuer)

      4/15/25 8:26:04 PM ET
      $TCRT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TCRT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Alaunos Therapeutics Inc.

      SC 13G/A - Alaunos Therapeutics, Inc. (0001107421) (Subject)

      11/14/24 4:06:27 PM ET
      $TCRT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Alaunos Therapeutics Inc. (Amendment)

      SC 13G/A - Alaunos Therapeutics, Inc. (0001107421) (Subject)

      2/14/24 12:43:20 PM ET
      $TCRT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Alaunos Therapeutics Inc. (Amendment)

      SC 13G/A - Alaunos Therapeutics, Inc. (0001107421) (Subject)

      2/13/24 4:58:29 PM ET
      $TCRT
      Biotechnology: Pharmaceutical Preparations
      Health Care